Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $61.28MP/E –Yield –
Acrivon Therapeutics cash
Cash and short-term investments held at the end of each period.
Acrivon Therapeutics's cash was $89.96M at Jun 30, 2026. For fiscal 2025 it was $118.58M, down 33.9% from the year before. The highest annual figure on record is $179.48M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.58M | -33.9% |
| FY2024 | Dec 31, 2024 | $179.48M | +40.8% |
| FY2023 | Dec 31, 2023 | $127.46M | -0.2% |
| FY2022 | Dec 31, 2022 | $127.75M | +28.3% |
| FY2021 | Dec 31, 2021 | $99.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $89.96M | -34.5% |
| Q1 FY2026 | Mar 31, 2026 | $97.74M | -34.7% |
| Q4 FY2025 | Dec 31, 2025 | $118.58M | -33.9% |
| Q3 FY2025 | Sep 30, 2025 | $129.25M | -31.0% |
| Q2 FY2025 | Jun 30, 2025 | $137.42M | -23.9% |
| Q1 FY2025 | Mar 31, 2025 | $149.64M | +36.1% |
| Q4 FY2024 | Dec 31, 2024 | $179.48M | +40.8% |
| Q3 FY2024 | Sep 30, 2024 | $187.45M | +31.9% |
| Q2 FY2024 | Jun 30, 2024 | $180.54M | +19.6% |
| Q1 FY2024 | Mar 31, 2024 | $109.98M | -8.5% |
| Q4 FY2023 | Dec 31, 2023 | $127.46M | -0.2% |
| Q3 FY2023 | Sep 30, 2023 | $142.09M | +85.0% |
| Q2 FY2023 | Jun 30, 2023 | $150.95M | +80.0% |
| Q1 FY2023 | Mar 31, 2023 | $120.21M | +32.4% |
| Q4 FY2022 | Dec 31, 2022 | $127.75M | +28.3% |
| Q3 FY2022 | Sep 30, 2022 | $76.80M | +2025.1% |
| Q2 FY2022 | Jun 30, 2022 | $83.86M | – |
| Q1 FY2022 | Mar 31, 2022 | $90.77M | – |
| Q4 FY2021 | Dec 31, 2021 | $99.60M | – |
| Q3 FY2021 | Sep 30, 2021 | $3.61M | – |
See a number that looks wrong?